Reckitt Benckiser beats earnings forecasts
LONDON Feb 13 (Reuters) - Britain's Reckitt Benckiser beat full-year earning expectations as the maker of Strepsils and Mucinex benefited from an unusually heavy U.S. cold and flu season in the final quarter.
Full-year adjusted earnings per share was 264.4 pence, compared to Thomson Reuters I/B/E/S estimates of 246.8 pence and a company-supplied forecast of 249 pence.
An early and unusually intense flu season in North America has pushed up business for hospitals, pharmacies and the makers of tissues and cold remedies.
- Malaysian plane presumed crashed; questions over false IDs |
- China draws 'red line' on North Korea, says won't allow war on peninsula
- Warning shots fired to turn monitors back from Crimea |
- Malaysian plane crashed off Vietnam coast: state media